BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 26264168)

  • 1. Managing perianal Crohn's fistula in the anti-TNFα era.
    Tozer P; Borowski DW; Gupta A; Yassin N; Phillips R; Hart A
    Tech Coloproctol; 2015 Nov; 19(11):673-8. PubMed ID: 26264168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment.
    de Groof EJ; Sahami S; Lucas C; Ponsioen CY; Bemelman WA; Buskens CJ
    Colorectal Dis; 2016 Jul; 18(7):667-75. PubMed ID: 26921847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of tumor necrosis factor-alpha inhibitors in fistulising perianal Crohn's disease].
    Bor R; Farkas K; Bálint A; Szűcs M; Abrahám S; Baradnay G; Wittmann T; Szepes Z; Nagy F; Molnár T
    Orv Hetil; 2013 Dec; 154(49):1943-8. PubMed ID: 24292112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anoperineal lesions in Crohn's disease: French recommendations for clinical practice.
    Bouchard D; Abramowitz L; Bouguen G; Brochard C; Dabadie A; de Parades V; Eléouet-Kaplan M; Fathallah N; Faucheron JL; Maggiori L; Panis Y; Pigot F; Rouméguère P; Sénéjoux A; Siproudhis L; Staumont G; Suduca JM; Vinson-Bonnet B; Zeitoun JD
    Tech Coloproctol; 2017 Sep; 21(9):683-691. PubMed ID: 28929282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn's disease.
    Haennig A; Staumont G; Lepage B; Faure P; Alric L; Buscail L; Bournet B; Moreau J
    Colorectal Dis; 2015 Apr; 17(4):311-9. PubMed ID: 25425534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure.
    Echarri A; Castro J; Barreiro M; Carpio D; Pereira S; Lorenzo A
    J Crohns Colitis; 2010 Dec; 4(6):654-60. PubMed ID: 21122576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas.
    Schwartz DA; White CM; Wise PE; Herline AJ
    Inflamm Bowel Dis; 2005 Aug; 11(8):727-32. PubMed ID: 16043987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without Luminal Crohn's Disease.
    McCurdy JD; Parlow S; Dawkins Y; Samji K; Rhee GG; Oliveira L; Macdonald B; Sabri E; Murthy S
    Dig Dis Sci; 2020 Jun; 65(6):1784-1789. PubMed ID: 31642006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease.
    Hukkinen M; Pakarinen MP; Piekkala M; Koivusalo A; Rintala R; Kolho KL
    J Crohns Colitis; 2014 Aug; 8(8):756-62. PubMed ID: 24447625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice.
    Bourikas LA; Koutroubakis IE
    Curr Drug Targets; 2010 Feb; 11(2):187-97. PubMed ID: 19916954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
    van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG
    Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
    Papamichael K; Cheifetz AS
    World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID).
    Le Baut G; Peyrin-Biroulet L; Bouguen G; Gornet JM; Stefanescu C; Amiot A; Laharie D; Altwegg R; Fumery M; Trang C; Vuitton L; Simon M; Gilletta de Saint Joseph C; Nahon S; Caillo L; Del Tedesco E; Plastaras L; Aubourg A; Pineton de Chambrun G; Seksik P; Viennot S
    Aliment Pharmacol Ther; 2018 Oct; 48(8):831-838. PubMed ID: 30194687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Gastroenterologist's Role in Management of Perianal Fistula.
    Dalal RL; Schwartz DA
    Gastrointest Endosc Clin N Am; 2016 Oct; 26(4):693-705. PubMed ID: 27633597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.
    Strik AS; Löwenberg M; Buskens CJ; B Gecse K; I Ponsioen C; Bemelman WA; D'Haens GR
    Scand J Gastroenterol; 2019 Apr; 54(4):453-458. PubMed ID: 31032686
    [No Abstract]   [Full Text] [Related]  

  • 17. Interdisciplinary Management of Perianal Crohn's Disease.
    Lightner AL; Faubion WA; Fletcher JG
    Gastroenterol Clin North Am; 2017 Sep; 46(3):547-562. PubMed ID: 28838414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial.
    de Groof EJ; Buskens CJ; Ponsioen CY; Dijkgraaf MG; D'Haens GR; Srivastava N; van Acker GJ; Jansen JM; Gerhards MF; Dijkstra G; Lange JF; Witteman BJ; Kruyt PM; Pronk A; van Tuyl SA; Bodelier A; Crolla RM; West RL; Vrijland WW; Consten EC; Brink MA; Tuynman JB; de Boer NK; Breukink SO; Pierik MJ; Oldenburg B; van der Meulen AE; Bonsing BA; Spinelli A; Danese S; Sacchi M; Warusavitarne J; Hart A; Yassin NA; Kennelly RP; Cullen GJ; Winter DC; Hawthorne AB; Torkington J; Bemelman WA
    Trials; 2015 Aug; 16():366. PubMed ID: 26289163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
    Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
    Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.